Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoki Fujita

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Plos One|September 15, 2025
Enhancing epidemic forecasting with a physics-informed spatial identity neural networkSatoki Fujita, Tatsuya Akutsu
Japanese Journal of Statistics and Data Science|June 22, 2022
Determination of optimal prevention strategy for COVID-19 based on multi-agent simulationSatoki Fujita, Ryo Kiguchi, Yuki Yoshida, et al.
Scientific Reports|August 10, 2023
Impact of meteorological and demographic factors on the influenza epidemic in Japan: a large observational database studyGenta Ito, Takahiro Takazono, Naoki Hosogaya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2022
Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims DatabaseShogo Miyazawa, Takahiro Takazono, Naoki Hosogaya, et al.
Journal of Affective Disorders|June 21, 2025
Predicting symptom worsening in remitted depression on maintenance pharmacotherapy using digital biomarkers: A prognostic modeling study using machine learningRyo Kiguchi, Ayano Hata, Satoki Fujita, et al.
Infectious Diseases and Therapy|August 27, 2025
Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir SharesAtaru Igarashi, Takahiro Takazono, Naoki Hosogaya, et al.
Infectious Diseases and Therapy|September 27, 2024
Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19"Takahiro Takazono, Satoki Fujita, Takuji Komeda, et al.
Infectious Diseases and Therapy|June 28, 2024
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19Takahiro Takazono, Satoki Fujita, Takuji Komeda, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Plos One|September 15, 2025
Enhancing epidemic forecasting with a physics-informed spatial identity neural networkSatoki Fujita, Tatsuya Akutsu
Japanese Journal of Statistics and Data Science|June 22, 2022
Determination of optimal prevention strategy for COVID-19 based on multi-agent simulationSatoki Fujita, Ryo Kiguchi, Yuki Yoshida, et al.
Scientific Reports|August 10, 2023
Impact of meteorological and demographic factors on the influenza epidemic in Japan: a large observational database studyGenta Ito, Takahiro Takazono, Naoki Hosogaya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2022
Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims DatabaseShogo Miyazawa, Takahiro Takazono, Naoki Hosogaya, et al.
Journal of Affective Disorders|June 21, 2025
Predicting symptom worsening in remitted depression on maintenance pharmacotherapy using digital biomarkers: A prognostic modeling study using machine learningRyo Kiguchi, Ayano Hata, Satoki Fujita, et al.
Infectious Diseases and Therapy|August 27, 2025
Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir SharesAtaru Igarashi, Takahiro Takazono, Naoki Hosogaya, et al.
Infectious Diseases and Therapy|September 27, 2024
Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19"Takahiro Takazono, Satoki Fujita, Takuji Komeda, et al.
Infectious Diseases and Therapy|June 28, 2024
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19Takahiro Takazono, Satoki Fujita, Takuji Komeda, et al.
Pageof 1